Back to Search
RICHARD PRATLEY, MD
MD
Endocrinology, Diabetes & Metabolism Physician
NPI: 1194837476IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine — Geriatric Medicine
Code: 207RG0300X
042-0010757(VT)ME110521(FL)
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
ME110521(FL)
Education
WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE
Class of 1983
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes.
PMID 36120427·Front Endocrinol (Lausanne)·2022
2-rct
Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes.
PMID 31757794·Diabetes·2020
2-rct
Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes.
PMID 26887289·Obesity (Silver Spring)·2016
2-rct
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
PMID 19191685·Expert Opin Pharmacother·2009
6-review
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
PMID 19125778·Diabetes Obes Metab·2009
4-observational
Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals.
PMID 19672057·Neuroendocrinology·2009
8-other
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
PMID 19580950·Eur J Intern Med·2009
6-review
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
PMID 19614942·Diabetes Obes Metab·2009
4-observational
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
PMID 19650752·Curr Med Res Opin·2009
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2415 N ORANGE AVE, SUITE 502
ORLANDO, FL 32804 - Phone
- (407) 303-2801
Quick Facts
- NPI
- 1194837476
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 43
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile